

10. REFERENCIAS

1. Armitage J. Bone Marrow Transplantation. *New England Journal of Medicine*. 1994;330:827-838.
2. Copelan E. Hematopoietic Stem-Cell Transplantation. *New England Journal of Medicine*. 2006;354:1813-1826.
3. Thomas ED, Lochte HL, Cannon JH, Sahler OD, Ferrebee JW. Supralethal whole body irradiation and isologous marrow transplantation in man. *Journal of Clinical Investigation*. 1959;38:1709-1716.
4. Ruiz-Argüelles GJ, Ruiz-Delgado GJ, Gómez-Almaguer D. Trasplante de Células Hematopoyéticas. En: Ruiz-Argüelles, *Fundamentos de Hematología*. México DF: Editorial Médica Panamericana; 2009. p. 317-321.
5. López-Karpovitch X. Hematopoyesis. En: Ruiz-Argüelles, *Fundamentos de Hematología*. México DF: Editorial Médica Panamericana; 2009. p.1-11.
6. Appelbaum, FR. Hematopoietic Cell Transplantation. In: Fauci, Braunwald, Kasper, Hauser, Longo, Jameson, Loscalzo. *Harrison's: Principles of Internal Medicine*. USA: McGraw Hill; 2008. p. 713-718.
7. Ruiz-Argüelles GJ, Cazares-Ordoñez Y, Ruiz-Delgado GJ. Algunas observaciones sobre el rezago en la práctica de trasplantes hematopoyéticos en México. *Revista de Hematología*. 2011;12(1):1-4
8. Mohar-Betancourt A. Trasplantes hematopoyéticos en el Instituto nacional de Cancerología. *Revista de Hematología*. 2011;12(2):117
9. Ruiz-Argüelles GJ. Historia del trasplante de médula ósea en México. *Revista Biomédica*. 2005;16:207-213
10. Baron F, Maris MB, Sandmaier BM, Storer BE, Sorrow M, Diaconescu R, et al. Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning. *Journal of Clinical Oncology*. 2005;23(9):1993-2003.
11. Ferrara JL, Yanik G. Acute Graft Versus Host Disease: Pathophysiology, Risk Factors, and Prevention Strategies. *Clinical advances in Hematology & Oncology*. 2005;3(5):415-419.

12. Jacobsohn DA, Vogelsang GB. Acute graft versus host disease. *Orphanet Journal of Rare Disease*. 2007;2(35):1-9.
13. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host-disease. *Biology of Blood and Marrow Transplantation*. 1999;5(6):347-356.
14. Cutler, C., Giri, S., Jeyapalan, S., Paniagua, D., Viswanathan, A., y Antin, J. Acute and Chronic Graft-Versus-Host Disease, After Allogeneic Peripheral-Blood Stem-Cell and Bone Marrow Transplantation: A Meta-Analysis. *Journal of Clinical Oncology*. 2001;19(16):3685-3691.
15. Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, Jaime-Pérez JC, Treviño-Montemayor OR, Martínez-Cabriales SA, Gómez-Peña A, et al. (2011). Low Incidence and severity of graft-versus-host disease after outpatient allogeneic peripheral blood stem cell transplantation employing a reduced-intensity conditioning. *European Journal of Haematology*. 2011:1-10.
16. Ratanatharathorn V, Ayasha L, Lazarus HM, Fu J, Uberti JP. Chronic graft-versus-host disease: clinical manifestation and therapy. *Bone Marrow Transplantation*. 2001;28:121:129.
17. Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. *British Journal of Haematology*. 1997;97:855-864.
18. Socié G, Blazar BR. Acute graft-versus-host disease: from the bench to the bed. *Blood*. 2009;114:4327-4336.
19. Lee SJ, Flower MED. Recognizing and Managing Chronic Graft-Versus-Host Disease. *Hematology*. 2008:134-141.
20. Subramaniam DS, Fowler DH, Pavletic SZ. Chronic graft-versus-host disease in the era of reduced-intensity conditioning. *Leukemia*. 2007;21:853-859.
21. Flower ME, Inamoto Y, carpenter PA, Lee AJ, Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National institutes of Health consensus criteria. *Blood*. 2011; 117:3214-3219.

22. Robertson P. Getting a handle on Graft-versus-Host Disease. *New England Journal of Medicine*. 2004;350(6):614-615.
23. Pollack SM, O'Connor TP, Hashash J, Tabbara IA. Nonmyeloablative and Reduced-Intensity Conditioning for Allogeneic Hematopoietic Stem Cell transplantation. A Clinical Review. *American Journal of Clinical Oncology*. 2009;32(6):618-628.
24. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, González-Llano O, Cantú OE, Hernández NE. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases. *Bone Marrow Transplantation*. 2010;25:131-133.
25. Ruiz-Delgado GJ, Hernández-Arizpe A, Macías-Gallardo J, Montes-Montiel M, Zamora-Ortiz G, Ruiz-Argüelles GJ. El programa de trasplantes de células hematopoyéticas de la Clínica Ruiz de Puebla (1992-2009). *Hematología*. 2010;11(1):15-20.
26. Ruiz-Argüelles GJ, Morales-Toquero A, López-Martínez B, Tarin-Arzaga LC, Manzano C. Bloodless (transfusión-free) hematopoietic stem cell transplants: the Mexican experience. *Bone Marrow Transplantation*. 2005:1-6.
27. Nakamura R, Auayporn N, Smith DD, Palmer F, Sun FY, Schriber F, et al. Impact of Graft Cell Dose on Transplant Outcomes following Unrelated Donor Allogeneic Peripheral Blood Stem Cell transplantation: Higher CD34+ Cell Doses Are Associated with Decreased relapse Rates. *Biology of Blood and Marrow Transplantation*. 2008;14:449-457.
28. Pérez-Simón JA, Díez-Campelo MD, Martino R, Sureda A, Caballero D, Cañizo C, et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. *Blood*. 2003;102:1108-1113.
29. Mohty M, Bilger K, Jourdan E, Kuentz M, Michallet M, Bourhis JH, et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. *Leukemia*. 2003;17:869-875.
30. Urbano-Ispizua A, Carreras E, Marín P, Rovira M, Martínez C, Fernández-Avilés F, et al. Allogeneic transplantation of CD34+ selected cells from peripheral blood from

human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34+ cells? *Blood*. 2001;98:2352-2357

31. Maciej-Zaucha J, Fooley T, Bensinger W, Heimfeld B, Chauncey T, Zaucha R, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. *Blood*. 2001;98:3221-3227
32. Tsirigotis P, Shapira MY, Or R, Bitan M, Samuel S, Gesundheit B, et al. The number of infused CD34+ cells does not influence the incidence of GVHD or the outcome of allogeneic PBSC transplantation, using reduced-intensity conditioning and antithymocyte globulin. *Bone Marrow Transplantation*. 2010;45:1189-119
33. Heimfeld S. Bone marrow transplantation: how important is CD34 cell dose in HLA-identical stem cell transplantation? *Leukemia*. 2003;17:856-858
34. Gorin NC, Piantadosi S, Stull M, Bonte H, Wingard JR, Civin C. Increased risk of lethal graft-versus-host disease-like syndrome after transplantation into NOD/SCID mice of human mobilized peripheral blood stem cells, as compared to bone marrow or cord blood. [abstract] *Journal of Hematotherapy and Stem Cell Research*. 2002;11(2):277-292
35. MacMillan ML, Weisdorf DJ, Brunstein CG, Cao Q, DeFor TE, Verneris MR, et al. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. *Blood*. 2009;113:2410-2415
36. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilized T helper 2-inducing dendritic cells. *Blood*. 2000;95(8):2484-2490
37. Macías-Guerra C, Ruiz-Delgado GJ, Manzano C, Díaz-Hernández MA, Tarín-Arzaga LC, González-Llano O. Umbilical cord blood transplantation using non-myeloablative conditioning: The Mexican experience
38. Lui H, Rich E, Godley L, Odenike O, Joseph L, Marino S, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD and durable remissions. *Blood*. 2001;118:6438-6445.

39. Ruiz-Delgado GJ, Mancias-Guerra DM, Macias-Gallardo J, González-Llano O, Hernández-Arispe A, Rodríguez-Romo LN, et al. Long-term results of placental blood allografting using reduced-intensity conditioning: multicenter experience in a developing country. *Hematology*. 2011;16(3):155-159
40. Narimatsu H, Kami M, Miyakoshi S, Murashige N, Yuji K, Hamaki T, et al. Graft failure following reduced-intensity cord blood transplantation for adult patients. *British Journal of Haematology*. 2005;132:36-41
41. Yasui K, Matsumoto K, Hirayama F, Tani Y, Nakano T. Differences Between Peripheral Blood and Cord Blood in the Kinetics of Lineage-Restricted Hematopoietic Cells: Implications for Delayed Platelet Recovery Following Cord Blood Transplantation. *Stem Cells*. 2003;21:143-151
42. Van-Rood JJ, Scaradavow A, Stevens CE. Indirect evidence that maternal microchimerism in cord blood mediates a graft-versus-leukemia effect in cord blood transplantation. *Proceedings of the national Academy of Sciences of the United States of America*. 2011;1-6